February 7, 2014
A New Tide Approaches
Simeprevir and sofosbuvir both represent a further step in the evolution of more effective, less-toxic HCV treatment options. But they, too, are just the beginning. Numerous direct-acting antiretrovirals are currently moving through the latter stage of the development pipeline, suggesting that the treatment landscape by early 2015 may look as different from the present as the present does from just a few years earlier.
For the notoriously hard-to-treat HCV genotype 1 in particular, Cox states: "It's hard to predict, but right now in advanced testing, there are some combinations that are inteferon-sparing" yet have very high sustained virologic response rates -- and may not even require the use of ribavirin.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|AIDS 2014 Video Blog #1: At MSM Global Forum, the Shock of Tragedy and the Road Forward|
|Coverage of AIDS 2014: The 20th International AIDS Conference|
|Triumeq (Tivicay + Epzicom) Becomes Newest Single-Pill HIV Treatment Regimen|
|Zero HIV Infections When PrEP Is Taken 4 or More Times a Week|
|AIDS 2014: Julio Montaner on the Proposed 90-90-90 Strategy to Help End HIV (Video)|
|The Grief That Keeps on Giving: Thoughts on HIV, Loss, and an Opportunity to Heal -- A Blog Entry by David Fawcett, Ph.D., L.C.S.W.|